
ACTU Stock Forecast & Price Target
ACTU Analyst Ratings
Bulls say
Actuate Therapeutics is well-positioned for future success due to its promising lead asset, elraglusib, which has shown activity in a variety of preclinical and clinical settings, including pediatric cancers and mPDAC. The company's strong financials, with $13.1M in cash and equivalents expected to support operations into 2026, and multiple opportunities for non-dilutive funding through Rare Pediatric Disease Designations and potential Priority Review Vouchers, provide a favorable outlook for development and commercialization of elraglusib. Additionally, the upcoming regulatory discussions with the FDA and EMA, along with the company's plans for a global Phase 3 registrational study, further demonstrate its commitment to advancing this promising drug candidate. Overall, the potential for elraglusib to address unmet medical needs, its versatility in multiple tumor types, and compelling clinical data support a positive outlook for Actuate Therapeutics.
Bears say
Actuate Therapeutics is a high-risk investment due to its clinical stage, reliance on a single drug in development, and lack of significant revenue generation. Additionally, the company has a high cash burn rate, with a significant portion of their cash coming from license revenues from a related party. This raises concerns about the sustainability of their operations and potential conflicts of interest. These factors suggest a negative outlook for Actuate Therapeutics' stock.
This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ACTU Analyst Forecast & Price Prediction
Start investing in ACTU
Order type
Buy in
Order amount
Est. shares
0 shares